NAD+ Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 12 weeks on, 4 weeks off (approximately 3 cycles per year); shorter 10-week and 4-week alternatives exist
• Frequency: Loading phase: daily to three times per week; Maintenance phase: once or twice per week
• Common delivery routes: Subcutaneous injection, intramuscular injection, intravenous infusion, oral precursors (NMN or NR)
• Key timing notes: Morning dosing strongly preferred; late-day or evening dosing disrupts sleep in most users

Who This Protocol Is For

NAD+ appeals to a wide range of people, and the goals they bring to a protocol vary considerably. The most common cluster around energy and cognitive performance: people who feel their mental clarity or stamina declining, whether gradually with age or acutely after illness, burnout, or chronic stress. A second group comes from the longevity and healthy aging space, drawn by NAD+'s role in DNA repair, mitochondrial function, and sirtuin pathway activation (switching on proteins that regulate aging and cellular repair). A third group is working through specific recovery challenges, including chronic fatigue, post-viral syndromes, and metabolic dysfunction, and is exploring NAD+ alongside other interventions.

Experience level shapes how the protocol is built. A first-time user needs to titrate slowly, starting conservatively and giving the body time to adapt before stepping up frequency. Someone who has run a full cycle before can return to an established maintenance frequency much faster after an off-cycle break.

Delivery route is the other major variable at the outset. Subcutaneous injection is the most common self-administered format. IV infusion delivers the highest amount per session but requires clinic access. Intramuscular injection sits between the two. Oral precursors like NMN and NR are a needle-free path that many people use to prime their system before moving to injectable protocols, or as a standalone approach that requires no cycling at all.

The protocol is not appropriate for everyone. People with active cancer, severe liver or kidney disease, or certain cardiovascular conditions should approach NAD+ only with close medical oversight, and some contraindications are absolute. Anyone in those categories should speak with a healthcare provider before going further.

How Is an NAD+ Cycle Structured?

The foundational shape of an injectable NAD+ cycle is loading, then maintenance, then a break.

The loading phase comes first. It lasts roughly one to two weeks, sometimes up to four for certain goals, and involves more frequent administration to bring intracellular NAD+ levels (the amount of NAD+ inside your cells) up quickly. Think of it like filling a reservoir that has been running low: you put in more volume at first to get the level up, then ease back once it is where you want it. The loading phase is not about a higher per-session amount; it is about higher frequency to build the baseline faster. The full mechanics are covered in the Loading and Maintenance Phases section below.

The maintenance phase follows and is where most of a cycle is spent. Frequency drops, and the goal shifts from building up to sustaining. A typical maintenance pattern is once or twice a week for subcutaneous protocols, or less frequent clinic visits for IV.

After the cycle ends, a break of roughly four weeks is the standard before restarting. Three cycles per year is the most commonly observed annual rhythm, giving roughly 36 weeks of active use and about 16 weeks of rest across the year. Shorter cycle structures of 10 weeks on and 8 weeks off, or 4 weeks on and 2 weeks off, appear in community protocols and suit users who prefer more frequent cycling.

Oral precursors like NMN and NR do not follow this cycling structure. They are taken daily and do not require an off-cycle break.

How Your Dose Is Determined

What moves an NAD+ dose:

• Your goal: The goal type is the biggest single factor. Energy and cognitive performance goals generally tend toward the lower end of the injectable range. Longevity protocols often sit in a similar band. Recovery from chronic illness, chronic fatigue, or acute metabolic challenges tends to sit toward the higher end of the injectable range. IV protocols, used most often for intensive recovery or detox applications, use significantly larger per-session amounts than subcutaneous protocols for the same person.
• Experience level: First-cycle users start well below where an experienced user maintains. Titrating up slowly in frequency is how tolerability is built. An experienced user can return to an established maintenance level much faster after an off-cycle break.
• Delivery route: Route changes everything about the dose. Oral precursors use fundamentally different amounts than subcutaneous injections, which are themselves different from IV infusion. The right number for subcutaneous use would be wrong for IV. Route is not a preference that can be swapped without recalculating the dose entirely.
• Individual response: Two people at the same goal, on the same route, with the same experience can respond very differently. Some users reach their target effect quickly; others titrate more slowly. Side effects during early sessions, particularly flushing, nausea, or an energy spike, are often a signal to slow down and start lower rather than push through.

There is no single dose that fits everyone running an NAD+ protocol. Goal, delivery route, and individual tolerance are the three factors that move it most, and getting the number right for your situation is exactly what a personalized protocol does.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, your delivery route, and your individual tolerance history and builds your NAD+ protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take NAD+?

Frequency depends on which phase of the protocol you are in and which delivery route you are using.

During the loading phase, subcutaneous protocols are typically run at two to three sessions per week for one to two weeks, or daily for a shorter intensive window of about one week. Daily loading is a front-loading technique to raise levels quickly, not a long-term maintenance strategy. IV protocols during loading may involve sessions every few days over two to four weeks.

During the maintenance phase, subcutaneous frequency drops to once or twice per week. Some longer-term maintenance approaches extend even further, with sessions every ten to fourteen days as stable levels are established. IV maintenance is typically scheduled monthly or every several weeks at a clinic.

Timing within the day is one of the clearest consensus points across clinical protocols and community reports: morning is the right time. NAD+ activates mitochondrial energy pathways (the cell machinery that produces energy), and that activation is genuinely stimulating. Late-day or evening sessions frequently disrupt sleep. Scheduling injections in the morning allows the energy and cognitive lift to track with the natural waking cycle. Consistency of schedule matters more than hitting an exact clock time: a user who keeps a consistent morning window will see more predictable results than one whose timing shifts day to day.

Loading and Maintenance Phases

The loading phase is where the cycle begins in earnest. For subcutaneous protocols, the most common structure is a more frequent injection schedule over the first one to two weeks. The goal is to saturate intracellular NAD+ levels (the amount of NAD+ inside your cells) from a depleted baseline up to a working range, which takes repeated dosing before the system reaches a steady state. The dose per session does not change between loading and maintenance; the frequency does. More sessions during loading is what builds the reservoir faster. Once levels are established, frequency is pulled back and maintenance begins.

For IV protocols, loading is more intensive: multiple clinic sessions over the first two to four weeks, often every few days, before dropping to far less frequent maintenance infusions. The total amount delivered per IV session is substantially larger than in subcutaneous protocols, and a provider administers it. Loading looks and feels different by route, but the logic is the same: front-load to build levels, then maintain at lower frequency.

Maintenance is the long tail of the cycle. For most subcutaneous users, it settles into a once-to-twice weekly rhythm that continues through the three-month on-cycle. Many users report that the benefits built during loading continue through maintenance without needing to return to the original loading frequency.

One practical note on the loading-to-maintenance transition: dropping frequency too abruptly can produce a brief subjective dip in energy or clarity for a few days. A gradual step-down over one to two weeks tends to avoid that gap more cleanly than an immediate switch.

Off-Cycle Considerations

The off-cycle break serves a real purpose in injectable NAD+ protocols. Continuous high-frequency dosing without a break can gradually reduce the protocol's effectiveness as the body adapts. A structured break resets that response and tends to make the next cycle more effective.

The standard break is four weeks, forming the one-month-off in the three-months-on, one-month-off annual structure. During that month, NAD+ levels gradually return toward baseline, which is the point. Some users report a subjective decline in energy or clarity toward the end of the break, a signal that the protocol was working and the restart will matter.

Restarting after a break should not go straight back to the maintenance frequency immediately. Most protocols call for restarting at a lower frequency, similar to but lighter than the original loading phase, before returning to the established maintenance level. Some users report needing less than before to reach the same effect after a break, suggesting the rest period improves sensitivity.

Community protocols also describe shorter cycling structures worth knowing: a 10-week-on, 8-week-off pattern popular among users who prefer more equal time on and off, and a 4-week-on, 2-week-off pattern for those who want a shorter, more frequent cycle rhythm. These are alternatives to the three-month standard, not replacements.

For oral NAD+ precursors, none of this applies. NMN and NR do not require cycling and are taken daily without a structured break.

What to Expect Week by Week

• Days 1 to 7: The earliest effects are subtle. Many users notice a slight lift in mood, more stable morning energy, or a mild improvement in daytime clarity within the first few days. Some commonly report feeling briefly fatigued in the first day or two as the body begins redirecting energy toward repair processes. Sleep quality improvements are commonly reported early, sometimes before energy changes become obvious.
• Week 2: Many users report that mental clarity becomes more consistent. Work productivity, focus, and resilience to stress are the areas most commonly described as improving. Exercise recovery is often a week-two observation: workouts feel less draining and bounce-back is faster.
• Weeks 3 to 4: Energy commonly becomes steadier throughout the day. Mood, motivation, and sleep quality are commonly reported as more stable. For users with chronic fatigue or post-illness goals, week three is often when the first meaningful shift is noticed.
• Beyond 4 weeks: Users who remain consistent through the full three-month cycle commonly report that improvements built in weeks two through four deepen and stabilize rather than plateau. Energy, cognitive clarity, and recovery quality hold at a higher baseline without requiring escalation of frequency.

These timelines reflect what users and practitioners commonly report across a wide range of protocols. Individual results vary by delivery route, consistency of schedule, and starting level of NAD+ depletion. What a well-run NAD+ cycle looks like when it goes right is often described the same way: steadier energy across the day, sharper cognition, better sleep, and a noticeable reduction in the fatigue or brain fog that brought someone to the protocol. The improvements tend to be cumulative rather than dramatic, building over weeks rather than appearing in a single session.

Common Protocol Mistakes

Starting too high, too fast. The most common mistake in injectable NAD+ protocols is beginning at a level the body is not prepared for. Too much too soon produces nausea, flushing, chest tightness, headaches, and an elevated heart rate that can be alarming. These are not signs the protocol is working; they are signals it opened too aggressively. The better-informed approach is to start conservatively and titrate up over the first two to three weeks before reaching the target maintenance level.

Injecting too quickly. Subcutaneous injection rate matters more for NAD+ than for most compounds. A rapid push delivers a concentrated bolus that frequently triggers flushing and chest-pressure responses similar to starting too high. Inject slowly and steadily. IV infusions should run slowly over several hours; a fast drip is one of the most common causes of acute side effects in clinic settings.

Dosing in the afternoon or evening. The energizing effect of NAD+ is real and well-established across clinical and community sources. Late-day sessions consistently disrupt sleep, sometimes significantly. Moving dosing to the morning resolves this for most users without any other change to the protocol.

Missing doses and doubling up. NAD+ protocols depend on consistent spacing between sessions to maintain stable levels. Skipping a session and then doubling the next dose does not produce the same effect and increases the risk of overload symptoms. The correct approach is to skip the missed session and resume at the next scheduled time.

Skipping the off-cycle break. Running injectable NAD+ continuously without a structured break gradually reduces its effectiveness. Users who skip the off-cycle period often report diminishing returns by the fourth or fifth month of uninterrupted use. The break is part of what keeps the protocol working over time.

Using degraded product. Reconstituted NAD+ is sensitive to storage conditions. Solution that has been left at room temperature, stored improperly, or appears cloudy, discolored, or particulate should not be used. Injecting degraded product is a direct cause of adverse reactions. Dry powder stores at room temperature; reconstituted solution requires refrigeration.

Sourcing from unverifiable suppliers. Product quality is one of the most consequential variables in any injectable protocol. Pharmaceutical-grade product from a supplier that provides a current certificate of analysis confirming sterility and potency is the standard. Unverifiable sources carry contamination and accuracy risks that no protocol structure can compensate for.

NAD+ is not FDA-approved as a therapeutic drug for human use and is administered as a compounded preparation. Athletes subject to anti-doping rules should verify current status with their relevant governing body before use.

Frequently Asked Questions

How long is a typical NAD+ cycle?

The most widely used structure is three months on followed by one month off, repeated approximately three times per year. Shorter alternatives of ten weeks on and eight weeks off, or four weeks on and two weeks off, appear in community protocols and suit users who prefer a different rhythm. The right cycle length depends on goal, delivery route, and individual response between cycles.

How often do you take NAD+?

Frequency depends on the phase and the delivery route. During loading, subcutaneous protocols are typically dosed two to three times per week or daily for a shorter intensive window. During maintenance, frequency drops to once or twice per week, with some long-term protocols extending to every ten to fourteen days. IV protocols follow a different pattern: loading sessions every few days at a clinic, then monthly or less frequent maintenance infusions.

Does NAD+ need a loading phase?

For injectable protocols, yes. A loading phase of one to two weeks at higher frequency is the standard approach for bringing intracellular NAD+ levels (the amount of NAD+ inside your cells) up to a working range before settling into steady maintenance. Oral precursors like NMN and NR do not require a loading phase and can be taken at a consistent daily amount from the start.

Do you need to cycle off NAD+?

For injectable and IV forms, yes. The standard is a four-week break after each three-month cycle, though shorter cycling structures with proportionally shorter breaks exist. The break resets the protocol's effectiveness and is one reason the next cycle tends to work well at a similar level. Oral precursors do not require cycling and are taken daily without a break period.

Can NAD+ be stacked with oral precursors?

Yes, and this is a common approach. Oral NMN or NR is frequently used for one to two weeks before starting an injectable loading phase, functioning as a primer that begins raising NAD+ levels through a gentler route. Some users continue oral precursors through the off-cycle break to slow the return to baseline, though this is a personal choice rather than a universal protocol requirement.

What should you expect during the first few sessions?

Early sessions, particularly subcutaneous injections, sometimes produce a transient flushing sensation, mild warmth, or a brief energy spike that can feel intense if the injection rate is too fast or the starting level is higher than the body is ready for. These effects generally settle within minutes and taper as tolerance builds over the first two weeks. Users who start conservatively and inject slowly report far fewer early-session side effects than those who begin aggressively.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for NAD+ in one place.